Memorial Sloan Kettering Cancer Center: Tri-Institutional Therapeutics Discovery Institute, Inc. Renews Partnerships With Takeda, Bridge Medicines, LLC
February 26, 2020
February 26, 2020
NEW YORK, Feb. 26 -- The Memorial Sloan Kettering Cancer Center issued the following news release:
Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.
A pioneering academic-industry collaboration, the Tri-I TDI was establis . . .
Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University, and Weill Cornell Medicine announced that the Tri-Institutional Therapeutics Discovery Institute, Inc. (Tri-I TDI) has renewed its collaborations with partners Takeda Pharmaceutical Company Limited (Takeda) and Bridge Medicines.
A pioneering academic-industry collaboration, the Tri-I TDI was establis . . .